16
Jan

Pfizer is well behind its rival titans in the race to cash in on a new class of cancer treatments. But instead of playing catch-up in skin cancer, the industry first immuno-oncology target, the drugmaker is skipping ahead to the next wave of malignancies.

…read more

Source: Playing catch-up, Pfizer looks to leapfrog Big Pharma’s immuno-oncology line

    

0 No comments